Evaluation of the cost per patient per injection of botulinum toxin a in upper limb spasticity: Comparison of two preparations in 19 countries

Medical Devices: Evidence and Research

Volumn 5, Issue 1, 2012, Pages 97-101

  Roze, Stéphane ^a   Kurth, Hannah ^b   Hunt, Barnaby ^c   Valentine, William ^c   Marty, Rémi ^a  

^a HEVA   (France)

^b IPSEN   (France)

^c Ossian Health Economics and Communications   (Switzerland)

Author keywords

Botox ; Botulinum toxin; Dysport ; Stroke; Upper limb spasticity

Indexed keywords

ALLERGAN; BOTULINUM TOXIN A; BOTULINUM TOXINS; COST ANALYSIS; LIST PRICES; MOVEMENT DISORDERS; NATIONAL LEVEL; PRODUCT CHARACTERISTICS; SPASTICITY; STROKE; UPPER LIMBS;

COST ACCOUNTING; COSTS; TOXIC MATERIALS;

COST BENEFIT ANALYSIS;

BOTULINUM TOXIN A;

ARM DISEASE; AUSTRALIA; BELGIUM; BRAZIL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DOSE RESPONSE; DRUG COST; ESTONIA; FRANCE; GEOGRAPHIC DISTRIBUTION; GERMANY; GREECE; HUMAN; HUNGARY; ITALY; KOREA; NETHERLANDS; POLAND; PORTUGAL; RECOMMENDED DRUG DOSE; REVIEW; RUSSIAN FEDERATION; SENSITIVITY ANALYSIS; SPAIN; SPASTICITY; SWEDEN; UKRAINE; UNITED KINGDOM; UNITED STATES;

EID: 84870351045     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: 10.2147/MDER.S35563     Document Type: Review

References (11)

1. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines. London, UK: Royal College of Physicians; 2009.
2. Gallichio JE. Pharmacologic management of spasticity following stroke. Phys Ther. 2004;84(10):973-981.
3. Shaw L, Rodgers H, Price C, et al. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technol Assess. 2010;14(26):1-113.
4. Bakheit AM, Zakine B, Maisonobe P, et al. The profle of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. Int J Rehabil Res. 2010;33(3):199-204.
5. Lundström E, Smits A, Borg J, et al. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the frst year after the event. Stroke. 2010;41(2):319-324.
6. Elovic E P, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008;89(5):799-806.
7. Keam SJ, Muir VJ, Deeks ED. Botulinum toxin A (Dysport®): in dys-tonias and focal spasticity. Drugs. 2011;71(8):1043-1058.
8. Oanda®. Historical exchange rates for the month of May 2011. Available from: http://www.oanda.com/currency/historical-rates/. Accessed September 13, 2012.
9. Roze S, Marty R, Kurth H, et al. Economic analysis of cost per episode of care for arm spasticity and cervical dystonia: comparison of two botulinum toxin A preparations in 20 countries. Presented at the International Society for Pharmacoeconomics and Outcomes Research 14th Annual European Congress, Madrid, Spain, November 5-8, 2011.
10. Shiue I. Age of onset for stroke delayed in the 21st century: what is next? Clin Neurol Neurosurg. 2011;113(9):725-726.
11. Slawek J, Bogucki A, Reclawowicz D. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, fexible injection regimens. Neurol Sci. 2005;26(1):32-39.